drugset / Trial / NCT00135837

Photodynamic Therapy in Occult-Only Lesions (POOL)

NCT00135837

Phase 4 Completed 202 enrolled Novartis QLT Inc. · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Age related macular degeneration is the leading cause of blindness for people over 50 in the western world. Blood vessels which start to grow form a lesion in the back of the eye. Verteporfin may stabilize the disease, by closing the blood vessels. This study will assess the efficacy and safety of verteporfin in patients with occult only lesions.

Timeline

Start
2003-06
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Verteporfin Other / unclassified